Inspire Investing LLC Has $354,000 Stock Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Inspire Investing LLC grew its stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 77.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 58,707 shares of the company’s stock after purchasing an additional 25,551 shares during the period. Inspire Investing LLC owned approximately 0.11% of ALX Oncology worth $354,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. CANADA LIFE ASSURANCE Co acquired a new position in shares of ALX Oncology during the first quarter valued at about $27,000. EntryPoint Capital LLC acquired a new stake in shares of ALX Oncology in the 1st quarter worth about $32,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of ALX Oncology by 66.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,587 shares of the company’s stock worth $107,000 after acquiring an additional 3,825 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after acquiring an additional 5,200 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of ALX Oncology by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock worth $333,000 after acquiring an additional 5,360 shares during the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

Insider Activity

In other news, insider Jaume Pons sold 20,000 shares of the stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $7.90, for a total transaction of $158,000.00. Following the completion of the transaction, the insider now directly owns 593,447 shares of the company’s stock, valued at approximately $4,688,231.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 28,398 shares of company stock valued at $200,043 in the last three months. Company insiders own 33.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. UBS Group lowered their target price on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 16th. Stifel Nicolaus restated a “hold” rating and issued a $3.00 target price (down previously from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a report on Tuesday, August 13th. Lifesci Capital lowered shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research note on Monday, August 12th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, ALX Oncology has an average rating of “Moderate Buy” and a consensus price target of $14.00.

ALX Oncology Trading Down 4.6 %

NASDAQ:ALXO opened at $2.07 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.39 and a current ratio of 4.39. The firm has a market cap of $107.85 million, a price-to-earnings ratio of -0.56 and a beta of 1.01. ALX Oncology Holdings Inc. has a 52 week low of $1.88 and a 52 week high of $17.83. The firm has a 50-day moving average price of $3.45 and a two-hundred day moving average price of $8.75.

ALX Oncology (NASDAQ:ALXO) last released its earnings results on Thursday, August 8th. The company reported ($0.76) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.01. On average, equities analysts expect that ALX Oncology Holdings Inc. will post -3.04 earnings per share for the current fiscal year.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.